ImmuCell Corporation (ICCC)

Market Cap	37.58M
Revenue (ttm)	21.28M
Net Income (ttm)	-3.90M
Shares Out	7.81M
EPS (ttm)	-0.51
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	26,553
Open	4.790
Previous Close	4.850
Day's Range	4.670 - 4.950
52-Week Range	4.340 - 6.050
Beta	0.61
Analysts	n/a
Price Target	n/a
Earnings Date	May 14, 2024

About ICCC

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides Califor...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 30, 1987
• Employees: 74
• Stock Exchange: NASDAQ
• Ticker Symbol: ICCC

Financial Performance

In 2023, ImmuCell's revenue was $17.47 million, a decrease of -5.90% compared to the previous year's $18.57 million. Losses were -$5.77 million, 131.6% more than in 2022.